David Seftel

Enable Biosciences, Inc. is a diagnostics company based in the United States. The private company is based in the United States. The American company develops and deploys bioassays for type 1 diabetes, COVID-19, and food allergy using licensed technology from UC. Enable Biosciences operates a CLIA certified high-complexity clinical reference laboratory and research facility. The company's proprietary diagnostics platform enables the ultrasensitive detection of biomarkers at the earliest stages of disease for optimal treatment timing. The company's fully automated high-throughput ultrasensitive and highly specific multiplex antibody detection analyzer uses its novel antibody detection by agglutination PCR (ADAP) chemistry to service clients in the infectious disease, autoimmunity, and allergy spaces. Enable has produced the independently-assessed world's best performing serologic tests for type 1 diabetes and HIV in oral fluid and other infectious diseases including Zika and Dengue. The company was founded by Jason Tsai, Carolyn R. Bertozzi, Peter Robinson, and David Seftel, with David Seftel serving as the CEO since incorporation.

Enable Biosciences, Inc. is a diagnostics company based in the United States. The private company is based in the United States. The American company develops and deploys bioassays for type 1 diabetes, COVID-19, and food allergy using licensed technology from UC. Enable Biosciences operates a CLIA certified high-complexity clinical reference laboratory and research facility. The company's proprietary diagnostics platform enables the ultrasensitive detection of biomarkers at the earliest stages of disease for optimal treatment timing. The company's fully automated high-throughput ultrasensitive and highly specific multiplex antibody detection analyzer uses its novel antibody detection by agglutination PCR (ADAP) chemistry to service clients in the infectious disease, autoimmunity, and allergy spaces. Enable has produced the independently-assessed world's best performing serologic tests for type 1 diabetes and HIV in oral fluid and other infectious diseases including Zika and Dengue. The company was founded by Jason Tsai, Carolyn R. Bertozzi, Peter Robinson, and David Seftel, with David Seftel serving as the CEO since incorporation.

Enable Biosciences, Inc. is a diagnostics company based in the United States. The private company is based in the United States. The American company develops and deploys bioassays for type 1 diabetes, COVID-19, and food allergy using licensed technology from UC. Enable Biosciences operates a CLIA certified high-complexity clinical reference laboratory and research facility. The company's proprietary diagnostics platform enables the ultrasensitive detection of biomarkers at the earliest stages of disease for optimal treatment timing. The company's fully automated high-throughput ultrasensitive and highly specific multiplex antibody detection analyzer uses its novel antibody detection by agglutination PCR (ADAP) chemistry to service clients in the infectious disease, autoimmunity, and allergy spaces. Enable has produced the independently-assessed world's best performing serologic tests for type 1 diabetes and HIV in oral fluid and other infectious diseases including Zika and Dengue. The company was founded by Jason Tsai, Carolyn R. Bertozzi, Peter Robinson, and David Seftel, with David Seftel serving as the CEO since incorporation.